An advisory panel to the agency voted 10-4 against approval of the drug with many of the members saying that the benefits of the drug were not enough to outweigh the risks. The panel also voted 12-2 against approving another drug, Depomed's Sefelsa, for similar reasons and added that three clinical trials did not show any marked reduction in hot flashes in menopausal women.
Depomed's chief executive, Jim Schoeneck said that his company will stop spending on Sefelsa unless the hurdles for approving similar drugs are not overcome. "Based on today's meeting we believe the hurdles for approval of a nonhormonal treatment for hot flashes remain high. Until we believe there is a positive direction for Sefelsa, we will cease all spending relating to the product candidate", he said.